3,4-dihydro-6-(4-pyridyl)isoquinolin-1(2H)-one | 1309955-18-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3,4-dihydro-6-(4-pyridyl)isoquinolin-1(2H)-one
• 英文别名: 6-pyridin-4-yl-3,4-dihydro-2H-isoquinolin-1-one
• CAS: 1309955-18-7
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: BYMLTKUKNPRHPJ-UHFFFAOYSA-N

物化性质

• 熔点：
  >190 °C (decomp)
• 沸点：
  523.2±50.0 °C(Predicted)
• 密度：
  1.197±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-6-(4-pyridyl)isoquinolin-1(2H)-one 在 sodium hydride 、 potassium carbonate 作用下， 以 4-甲基-2-戊酮 、 苯 为溶剂， 反应 50.0h， 生成 USC-M401
  参考文献：
  名称：

  Aromatic ring functionalization of benzolactam derivatives: New potent dopamine D3 receptor ligands

  摘要：

  Since the discovery of the dopamine D-3 receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D-3 receptors. As a part of our efforts, a novel series of substituted benzolactams derivatives was synthesized mostly through palladium-catalyzed reactions. Their affinities on D-1-D-4 receptors were evaluated and the data led us to highly potent D-3 ligands, some of them highly selective for D-3 receptor, compared to the related dopamine receptor subtypes. Functional D-3 activity assays of the most relevant compounds have been carried out revealing antagonist as well as partial agonist activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.083
• 作为产物：
  描述：

  5-溴茚酮 在 四(三苯基膦)钯 、 sodium azide 、 potassium carbonate 作用下， 以 甲烷磺酸 、 二氯甲烷 、 甲苯 为溶剂， 反应 6.33h， 生成 3,4-dihydro-6-(4-pyridyl)isoquinolin-1(2H)-one
  参考文献：
  名称：

  Aromatic ring functionalization of benzolactam derivatives: New potent dopamine D3 receptor ligands

  摘要：

  Since the discovery of the dopamine D-3 receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D-3 receptors. As a part of our efforts, a novel series of substituted benzolactams derivatives was synthesized mostly through palladium-catalyzed reactions. Their affinities on D-1-D-4 receptors were evaluated and the data led us to highly potent D-3 ligands, some of them highly selective for D-3 receptor, compared to the related dopamine receptor subtypes. Functional D-3 activity assays of the most relevant compounds have been carried out revealing antagonist as well as partial agonist activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.083

文献信息

• [EN] BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME<br/>[FR] DÉRIVÉS BENZAMIDES MODULATEURS ALLOSTÉRIQUES POSITIFS RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE 5 (MGLUR5) ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV VANDERBILT

  公开号：WO2008151184A1

  公开（公告）日：2008-12-11

  [EN] In one aspect, the invention relates to compounds, including benzamide derivatives and cyclic benzamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
  [FR] Selon un aspect, la présente invention concerne des composés, comprenant des dérivés benzamides et des dérivés benzamides cycliques, qui sont utiles en tant que modulateurs positifs allostériques du récepteur de sous-type 5 du glutamate (mGluR5); des procédés synthétiques pour la fabrication des composés; des compositions pharmaceutiques comportant les composés; et des procédés de traitement de troubles neurologiques et psychiatriques associés au dysfonctionnement glutamatergique mettant en uvre les composés et les compositions. Cet abrégé est soumis afin de permettre une recherche générale dans ce domaine précis et ne doit pas être utilisé pour limiter la portée de la présente invention.